President Donald Trump has signed legislation delaying most of the sweeping federal restrictions scheduled to hit hemp-derived THC and cannabinoid products this fall. The White House confirmed that Trump signed H.R. 6500, the Continuing Appropriations and Extensions Act, 2027, on September 2, 2026. The broader measure keeps the federal government funded through December 11, but buried inside it is Section 2019, a provision that effectively postpones most of the new federal hemp restrictions from November 12 until December 11, 2026.
The signature ends weeks of uncertainty over whether Congress’s temporary hemp reprieve would actually become law. The Senate approved H.R. 6500 by 90-6 on August 8, and the House followed on September 1 with an overwhelming 370-48 vote to accept the Senate amendments. Those margins show substantial bipartisan willingness to postpone the crackdown, but they should not be confused with congressional agreement on what should replace it. Hemp-derived THC drinks, gummies, full-spectrum CBD products and other cannabinoid goods now have roughly another month of federal breathing room, while lawmakers attempt to decide whether the industry should face strict prohibition or a new national regulatory structure.
What Trump Actually Signed Into Law
Section 2019 is only a few lines long, but its legal effect is significant. The enacted text states that until December 11, the amendments made by Section 781 of the 2025 agriculture appropriations law will apply only to two specific categories: intermediate and finished products containing cannabinoids that cannot naturally be produced by Cannabis sativa. Most of the remaining provisions of the new hemp definition are therefore temporarily held back.
That distinction is important. Headlines describing the legislation as a blanket delay of a “hemp ban” are directionally correct but incomplete. Congress did not suspend every provision scheduled for November 12. Products containing cannabinoids that cannot occur naturally in cannabis remain subject to the new exclusion at that time. By contrast, restrictions affecting naturally occurring cannabinoids, cannabinoids synthesized outside the plant, total-THC measurements and the controversial finished-product THC limit generally do not take full effect until December 11 under the new law.
The delay also does not permanently repeal anything. Unless Congress passes another law before December 11, the broader changes enacted in 2025 will take effect automatically. The hemp industry has gained about four additional weeks—not a permanent exemption.
The Coming Hemp Rules Are Much Broader Than a Delta-8 Ban
The controversy originates with Section 781 of Public Law 119-37, enacted November 12, 2025. Congress rewrote the federal definition of hemp first established by the 2018 Farm Bill, which currently defines legal hemp primarily through a limit of 0.3 percent delta-9 THC by dry weight. Under the new definition, federal law instead considers total tetrahydrocannabinols, including THCA, and creates separate restrictions for intermediate and finished cannabinoid products.
For consumer products, the most disruptive provision is a limit of only 0.4 milligrams combined total per container of THC and cannabinoids determined to have similar effects. “Container” means the innermost retail package directly holding the product—such as a bottle, can, bag, jar, cartridge or box. The limit therefore applies to the entire retail package rather than each serving. A package of ten gummies containing 5 milligrams of hemp-derived THC each would not be judged against a 5-milligram serving; the entire 50 milligrams would count toward a federal ceiling of 0.4 milligrams.
That threshold explains why industry groups describe the policy as a de facto prohibition rather than a conventional potency limit. Many intoxicating hemp gummies, drinks and tinctures exceed 0.4 milligrams by orders of magnitude. But the provision can also capture some full-spectrum CBD products containing only trace amounts of naturally occurring THC. A large bottle with tiny amounts per serving can still exceed the container-wide limit once all servings are added together.
Full-Spectrum CBD Is Part of the Debate
The possible loss of full-spectrum CBD products has become one of the most important reasons the Trump administration backed revisiting the 2025 law. In a December 2025 executive order addressing marijuana and CBD research, Trump explicitly directed White House officials to work with Congress to update the statutory definition of final hemp-derived cannabinoid products so consumers could continue accessing “appropriate full-spectrum CBD products” while products posing serious health risks remained restricted.
The same order went further than simply requesting a carve-out. It directed federal officials to explore a regulatory framework that could include THC limits per serving, per-container limits and CBD-to-THC ratio requirements. That language suggests the administration is open to a model in which some cannabinoid products remain federally legal but are governed by clearer dosage and safety standards rather than an across-the-board 0.4-milligram threshold.
Trump’s signature on H.R. 6500 therefore fits with the administration’s previously stated position. It does not mean the White House supports unrestricted hemp-derived THC sales. Instead, the administration has signaled interest in preserving some lawful cannabinoid products while creating tighter rules around products capable of intoxication.
Congress Now Has Until December 11 to Find a Permanent Solution
Several lawmakers are already pushing alternatives. Reps. Andy Barr of Kentucky and Angie Craig of Minnesota introduced the Lawful Hemp Protection Act, H.R. 9830, which is specifically intended to preserve lawful hemp commerce while restricting high-THC synthetic intoxicants and establishing a more conventional federal regulatory system. The proposal has been referred to the House Agriculture, Energy and Commerce, Ways and Means, and Transportation and Infrastructure committees.
Rep. Morgan Griffith of Virginia is promoting another approach through the Hemp Enforcement, Modernization, and Protection Act, or HEMP Act. Griffith says the proposal would create an FDA-centered regulatory pathway for CBD and other hemp-derived products instead of relying on the largely fragmented state-by-state system that exists today. After the House approved H.R. 6500, Griffith argued that producers and consumers need federal standards built around oversight, responsibility and safety.
Other lawmakers have proposed much longer delays. The bipartisan Hemp Planting Predictability Act, introduced in the Senate by Amy Klobuchar, Rand Paul and Jeff Merkley, would change the original implementation period from one year to three years. That would postpone the 2025 restrictions far beyond December and give Congress substantially more time to write a permanent framework. The short H.R. 6500 extension reflects part of that effort but does not enact the three-year delay.
Supporters of the Crackdown Say Congress Is Delaying Needed Consumer Protections
Not everyone views Trump’s signature as good news. A bipartisan coalition of 35 state and territorial attorneys general urged Congress in August not to delay, repeal or weaken the hemp reforms. Their argument is that the 2018 Farm Bill created a loophole allowing intoxicating products to spread through gas stations, smoke shops, online stores and other retailers without consistent age restrictions or marijuana-style regulations.
Those concerns are not limited to whether adults should be able to purchase THC beverages. State regulators have repeatedly highlighted products packaged like candy, inconsistent laboratory testing, uncertain doses and youth access. California Attorney General Rob Bonta argued that intoxicating items designed to resemble common snack foods created avoidable risks for children and consumers. The attorneys general contend that the stricter federal definition gives law enforcement clearer lines between agricultural hemp and intoxicating cannabinoid products.
The political fight is therefore increasingly between two different forms of federal intervention. One side favors allowing the restrictive definition enacted in 2025 to take effect. The other favors keeping cannabinoid commerce legal but imposing age limits, testing, labeling, potency restrictions and manufacturing controls similar to those used for other regulated consumer products.
The New Law Does Not Override State Hemp Restrictions
Trump’s signature also does not automatically reopen hemp markets in states that have adopted their own bans or restrictions. Federal hemp status sets an important baseline under federal law, but states retain substantial authority to regulate or prohibit cannabinoid products within their borders. Some states have already restricted delta-8 THC, THCA flower, hemp-derived delta-9 beverages or other consumable cannabinoid products independently of the federal deadline.
For businesses, that means the December 11 extension should not be read as nationwide permission to sell every hemp product until December. A product must still comply with applicable state food, drug, cannabis, age-verification, labeling and cannabinoid rules. The federal change primarily preserves the existing federal hemp definition for most products during the additional transition period.
That distinction is particularly relevant to national retailers and online sellers. A product may remain federally classified as hemp during the delay while still being illegal to sell in a particular state. Conversely, a state may authorize a hemp THC product that could lose federal hemp protection if Congress allows the new definition to take full effect in December.
December Could Determine the Future of the Hemp THC Industry
Industry supporters are treating the extension as a final opportunity rather than a victory lap. The U.S. Hemp Roundtable’s Jonathan Miller described the roughly 30-day extension as a lifeline and called for Congress to use December negotiations to adopt rules that prevent sales to minors, protect farmers and preserve access to hemp and CBD products used by adults. State-regulated cannabis interests, meanwhile, continue to argue that hemp intoxicants have been able to compete with licensed marijuana businesses without facing equivalent taxes and compliance requirements.
That conflict is likely to intensify because the commercial stakes are substantial. Hemp-derived THC beverages increasingly compete with alcoholic drinks, while gummies, vapes and flower compete more directly with licensed cannabis markets. Full-spectrum CBD occupies still another category, often marketed toward wellness rather than intoxication. A single 0.4-milligram-per-container rule treats those markets similarly even though their products, consumers and risk profiles can be very different.
The central policy question Congress now faces is whether it can separate those categories intelligently. A national system could distinguish non-intoxicating CBD from intoxicating THC products, restrict certain synthetic compounds, establish adult-only sales, require laboratory testing and impose serving-size limits. But designing that system—and agreeing which federal agency should supervise it—is considerably harder than changing the definition of hemp.
Trump’s Signature Changes the Deadline, Not the Final Outcome
The immediate development is clear: President Trump signed H.R. 6500 on September 2, and most of the federal hemp restrictions that were scheduled to become effective November 12 are now held back until December 11, 2026. Certain cannabinoids that cannot naturally occur in cannabis remain outside that temporary reprieve.
What happens after December 11 is much less certain. Congress could enact a comprehensive regulatory bill, extend the deadline again, create carve-outs for CBD or low-dose THC products, or allow the entire 2025 framework to take effect. The latter would likely remove federal hemp protection from a large share of today’s consumable cannabinoid market because of the total-THC standard, synthetic-cannabinoid restrictions and extremely low finished-product threshold.
Trump’s signature therefore does not end the federal hemp fight—it intensifies the countdown. Congress now has only a short window to decide whether the national hemp market should be governed primarily through prohibition or transformed into a regulated cannabinoid industry with federal standards for potency, testing, labeling and access. For hemp farmers, CBD manufacturers, THC beverage companies, licensed cannabis operators and millions of consumers, December 11 has become the next major date to watch.
